Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

A number of other research analysts have also weighed in on the company. Weiss Ratings raised Ironwood Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, August 7th. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.23.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock opened at $4.29 on Friday. The firm has a market capitalization of $708.88 million, a P/E ratio of 5.57 and a beta of 0.20. Ironwood Pharmaceuticals has a one year low of $1.01 and a one year high of $5.78. The business has a fifty day moving average price of $4.08 and a 200-day moving average price of $3.92.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The company had revenue of $113.04 million for the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a net margin of 33.36% and a negative return on equity of 58.38%. Sell-side analysts expect that Ironwood Pharmaceuticals will post 1.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Ronald Silver sold 127,890 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total transaction of $578,062.80. Following the completion of the transaction, the insider directly owned 313,680 shares in the company, valued at $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julie Mchugh sold 21,571 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the transaction, the director owned 250,749 shares in the company, valued at $935,293.77. This represents a 7.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 9.30% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Large investors have recently modified their holdings of the business. LSV Asset Management purchased a new position in shares of Ironwood Pharmaceuticals during the fourth quarter worth about $30,000. Jump Financial LLC purchased a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $34,000. DGS Capital Management LLC bought a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $35,000. Cibc World Markets Corp bought a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $36,000. Finally, Simplify Asset Management Inc. bought a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $37,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.